A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)

被引：0

作者：

Jordi Rodon

Charlotte D. Jacobs

Quincy Chu

Eric K. Rowinsky

Arturo Lopez-Anaya

Chris H. Takimoto

Heather A. Wakelee

机构：

[1] Cancer Therapy and Research Center at The University of Texas Health Science Center,Institute for Drug Development

[2] Stanford University and Stanford Cancer Institute,Division of Oncology, Department of Medicine

[3] Eisai,undefined

[4] Inc.,undefined

[5] Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology,undefined

[6] Cross Cancer Institute,undefined

[7] University of Alberta,undefined

[8] Oncodrugs Consulting,undefined

[9] Forest Laboratories,undefined

[10] Inc.,undefined

[11] Ortho Biotech Oncology R&D/Johnson & Johnson,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2012年 / 69卷

关键词：

Bexarotene; Carboplatin; Paclitaxel; Pharmacokinetics; Phase I;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：825 / 834

页数：9

共 50 条

[21] Phase I Clinical and Pharmacokinetic Study of Bi-weekly Carboplatin/Paclitaxel Chemotherapy in Elderly Patients with Advanced Non-small Cell Lung Cancer
Tsubata, Yukari
Okimoto, Tamio
Miura, Kiyotaka
Karino, Fumi
Iwamoto, Shinichi
Tada, Mitsuhiro
Honda, Takeshi
Hamaguchi, Shunichi
Ohe, Miki
Sutani, Akihisa
Kuraki, Takashige
Hamada, Akinobu
Isobe, Takeshi
ANTICANCER RESEARCH, 2013, 33 (01) : 261 - 266
[22] A Phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer
Kelly, K
Pan, ZX
Murphy, J
Huffman, DH
Bunn, PA
CLINICAL CANCER RESEARCH, 1997, 3 (07) : 1117 - 1123
[23] A phase II study of carboplatin and paclitaxel as first line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC)
Giorgio, CG
Pappalardo, A
Russo, A
Giuffrida, D
Santini, D
Petralia, G
Castorina, S
Nunzio, R
Failla, G
Bordonaro, R
LUNG CANCER, 2006, 51 (03) : 357 - 362
[24] Phase I/II study of carboplatin and weekly paclitaxel for advanced non-small cell lung cancer.
Ohashi, N
Arita, KI
Daga, H
Mito, A
Nishino, R
Moritani, C
Nakamura, K
Daido, K
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 687S - 687S
[25] Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancer
Scagliotti, GV
Crinó, L
Pozzi, E
Corgna, E
Selvaggi, G
Novello, S
Salsano, G
Gentile, A
Palladino, M
Marracolo, F
Tonato, M
LUNG CANCER, 1999, 25 (01) : 39 - 46
[26] Effect of bexarotene on vinorelbine and cisplatin pharmacokinetics during a Phase I study in patients with advanced non-small cell lung cancer (NSCLC)
Wakelee, H
Middleton, G
Dunlop, D
Kelly, C
Ramlau, R
Leighl, N
Hao, D
Zatloukal, P
Cox, K
Loewen, G
LUNG CANCER, 2005, 49 : S274 - S274
[27] Phase I study of gemcitabine (GEM) and carboplatin (CBDCA) in advanced non-small cell lung cancer (NSCLC).
Kawabata, S
Oka, M
Fukuda, M
Kinoshita, A
Fukuda, M
Nagashima, S
Nakamura, Y
Nakano, H
Soda, H
Kohno, S
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 688S - 688S
[28] A phase III randomized trial of carboplatin/paclitaxel, with or without bexarotene (Targretin®), in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC)
Gatzemeier, U
Blumenschein, G
Jotte, R
von Pawel, J
Miller, W
Khuri, F
Rigas, J
Mabry, M
Dziewanowska, Z
Negro-Vilar, A
LUNG CANCER, 2005, 49 : S31 - S31
[29] Phase II study of carboplatin and weekly paclitaxel in advanced non-small cell lung cancer
Nakadate, Megumi
Yamazaki, Koichi
Konishi, Jun
Kinoshita, Ichiro
Sukoh, Noriaki
Harada, Masao
Akie, Kenji
Ogura, Shigeaki
Ishida, Takashi
Munakata, Mitsuru
Dosaka-Akita, Hirotoshi
Isobe, Hiroshi
Nishimura, Masaharu
ANTICANCER RESEARCH, 2006, 26 (5B) : 3767 - 3772
[30] Paclitaxel Carboplatin in Elderly Patients with Advanced Non-Small Cell Lung Cancer
Kanat, Ozkan
Cubukcu, Erdem
Cubukcu, Sinem
Aksoy, Savas
Canhoroz, Mustafa
Karadag, Oya
Alkis, Nihan
Manavolglu, Osman
JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE, 2012, 3 (03) : 293 - 295

← 1 2 3 4 5 →